1. Home
  2. RGNT vs BTAI Comparison

RGNT vs BTAI Comparison

Compare RGNT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

N/A

Current Price

$3.38

Market Cap

20.4M

Sector

Health Care

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

N/A

Current Price

$1.59

Market Cap

35.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RGNT
BTAI
Founded
2004
2017
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.4M
35.6M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
RGNT
BTAI
Price
$3.38
$1.59
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$25.33
AVG Volume (30 Days)
6.8K
952.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$261.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.10
$1.17
52 Week High
$8.35
$8.08

Technical Indicators

Market Signals
Indicator
RGNT
BTAI
Relative Strength Index (RSI) 29.61 47.69
Support Level N/A $1.50
Resistance Level $4.40 $2.18
Average True Range (ATR) 0.26 0.14
MACD 0.02 0.01
Stochastic Oscillator 19.23 38.16

Price Performance

Historical Comparison
RGNT
BTAI

About RGNT Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: